A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of Lapatinib (GW572016) in Combination With Paclitaxel Versus Paclitaxel Plus Placebo in Subjects With ErbB2 Amplified Metastatic Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Lapatinib (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms CHINA
- Sponsors GlaxoSmithKline; Novartis
- 08 Jan 2018 Planned End Date changed from 21 Dec 2017 to 31 Dec 2020.
- 25 Jan 2017 Planned End Date changed from 1 Mar 2017 to 21 Dec 2017.
- 28 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Mar 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History